| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Constance M Moore, Joseph Biederman, Janet Wozniak, Eric Mick, Megan Aleardi, Megan Wardrop, Meghan Dougherty, Terri Harpold, Paul Hammerness, Edin Randall, In Kyoon Lyoo, Perry F Rensha. Mania, glutamate/glutamine and risperidone in pediatric bipolar disorder: a proton magnetic resonance spectroscopy study of the anterior cingulate cortex. Journal of affective disorders. vol 99. issue 1-3. 2007-06-14. PMID:17005256. |
the purpose of this study was to investigate the anterior cingulate cortex (acc) glutamate/glutamine (glx) to creatine ratio (glx/cr) in two groups of children with bipolar disorder (bpd): those exhibiting manic symptoms requiring treatment and those being stably treated with the atypical antipsychotic risperidone. |
2007-06-14 |
2023-08-12 |
human |
| Gaetana Migliardi, Concetta D'Arrigo, Vincenza Santoro, Antonio Bruno, Lara Cortese, Domenica Campolo, Massimo Cacciola, Edoardo Spin. Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders. Clinical neuropharmacology. vol 30. issue 2. 2007-06-13. PMID:17414943. |
to investigate the effect of topiramate on the steady-state plasma concentrations of the second-generation antipsychotics--clozapine, olanzapine, risperidone, and quetiapine--in patients with schizophrenia or bipolar disorder. |
2007-06-13 |
2023-08-12 |
Not clear |
| Terence A Ketter, Henry A Nasrallah, Andrea Fagiolin. Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder. Psychopharmacology bulletin. vol 39. issue 1. 2007-04-03. PMID:17065977. |
the authors reviewed the literature on the efficacy of agents with the best clinical evidence supporting their use in bipolar disorder, including the mood stabilizers lithium, valproate, lamotrigine, and carbamazepine, as well as the atypical antipsychotics olanzapine, risperidone, quetiapine, ziprasidone, and aripiprazole. |
2007-04-03 |
2023-08-12 |
Not clear |
| Reiji Yoshimura, Yuichiro Nakano, Hikaru Hori, Atsuko Ikenouchi, Nobuhisa Ueda, Jun Nakamur. Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. Human psychopharmacology. vol 21. issue 7. 2007-01-26. PMID:17029305. |
effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. |
2007-01-26 |
2023-08-12 |
human |
| Reiji Yoshimura, Yuichiro Nakano, Hikaru Hori, Atsuko Ikenouchi, Nobuhisa Ueda, Jun Nakamur. Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. Human psychopharmacology. vol 21. issue 7. 2007-01-26. PMID:17029305. |
in the present study, the authors investigated the efficacy of risperidone treatment for both acute manic and depressive episodes in bipolar disorder. |
2007-01-26 |
2023-08-12 |
human |
| J M Rendell, J R Gedde. Risperidone in long-term treatment for bipolar disorder. The Cochrane database of systematic reviews. issue 4. 2007-01-19. PMID:17054229. |
risperidone in long-term treatment for bipolar disorder. |
2007-01-19 |
2023-08-12 |
Not clear |
| R Yoshimura, N Ueda, K Shinkai, J Nakamur. Two cases of bipolar disorder successfully stabilized for five years with a low dose of risperidone and lithium. Pharmacopsychiatry. vol 39. issue 6. 2007-01-11. PMID:17124648. |
two cases of bipolar disorder successfully stabilized for five years with a low dose of risperidone and lithium. |
2007-01-11 |
2023-08-12 |
Not clear |
| Edoardo Spina, Concetta D'Arrigo, Gaetana Migliardi, Vincenza Santoro, Maria Rosaria Muscatello, Umberto Micò, Giuseppina D'Amico, Emilio Perucc. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Therapeutic drug monitoring. vol 28. issue 5. 2007-01-09. PMID:17038872. |
effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. |
2007-01-09 |
2023-08-12 |
Not clear |
| Edoardo Spina, Concetta D'Arrigo, Gaetana Migliardi, Vincenza Santoro, Maria Rosaria Muscatello, Umberto Micò, Giuseppina D'Amico, Emilio Perucc. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Therapeutic drug monitoring. vol 28. issue 5. 2007-01-09. PMID:17038872. |
the effect of lamotrigine on the steady-state plasma concentrations of the atypical antipsychotics clozapine, olanzapine, and risperidone was investigated in patients with schizophrenia or bipolar disorder stabilized on chronic treatment with clozapine (200-500 mg/day; n = 11), risperidone (3-6 mg/day; n = 10) or olanzapine (10-20 mg/day; n = 14)). |
2007-01-09 |
2023-08-12 |
Not clear |
| Mani N Pavuluri, David B Henry, Julie A Carbray, Gwen A Sampson, Michael W Naylor, Philip G Janica. A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder. Journal of child and adolescent psychopharmacology. vol 16. issue 3. 2006-11-07. PMID:16768641. |
a one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder. |
2006-11-07 |
2023-08-12 |
Not clear |
| Mani N Pavuluri, David B Henry, Julie A Carbray, Gwen A Sampson, Michael W Naylor, Philip G Janica. A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder. Journal of child and adolescent psychopharmacology. vol 16. issue 3. 2006-11-07. PMID:16768641. |
the aim of this study was to assess the safety and efficacy of risperidone augmentation of lithium in preschool-onset bipolar disorder (bd) among youth who insufficiently respond to lithium monotherapy. |
2006-11-07 |
2023-08-12 |
Not clear |
| Salvatore Gentil. Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers. Bipolar disorders. vol 8. issue 3. 2006-10-31. PMID:16696822. |
in the last few years several investigations have evaluated the efficacy of emerging mood-stabilizing agents in the treatment of bipolar disorders, such as lamotrigine, olanzapine, risperidone, quetiapine, aripiprazole and ziprasidone. |
2006-10-31 |
2023-08-12 |
Not clear |
| Kirti Saxena, Kiki Chang, Hans Steine. Treatment of aggression with risperidone in children and adolescents with bipolar disorder: a case series. Bipolar disorders. vol 8. issue 4. 2006-10-03. PMID:16879141. |
treatment of aggression with risperidone in children and adolescents with bipolar disorder: a case series. |
2006-10-03 |
2023-08-12 |
Not clear |
| Kirti Saxena, Kiki Chang, Hans Steine. Treatment of aggression with risperidone in children and adolescents with bipolar disorder: a case series. Bipolar disorders. vol 8. issue 4. 2006-10-03. PMID:16879141. |
to evaluate the effectiveness and safety of risperidone in children and adolescents with bipolar disorder characterized by aggression and mania, despite treatment with mood stabilizers. |
2006-10-03 |
2023-08-12 |
Not clear |
| Rachael L Fleurence, Julia M Dixon, Dennis A Revick. Economics of atypical antipsychotics in bipolar disorder: a review of the literature. CNS drugs. vol 20. issue 7. 2006-09-05. PMID:16800717. |
based on the limited available studies, there appears to be no significant difference in healthcare resource use between olanzapine, quetiapine, risperidone and valproate semisodium (divalproex sodium; an antiepileptic drug and a standard treatment for mania associated with bipolar disorder). |
2006-09-05 |
2023-08-12 |
Not clear |
| Andreas Schreine. [Treatment of bipolar mania with risperidone]. Psychiatrische Praxis. vol 33 Suppl 1. 2006-07-06. PMID:16511726. |
this review summarizes the available literature on risperidone in the treatment of bipolar disorders. |
2006-07-06 |
2023-08-12 |
Not clear |
| Sumant Khann. Risperidone effectively increases rates of symptomatic remission of acute mania in people with bipolar disorder. Evidence-based mental health. vol 9. issue 2. 2006-05-18. PMID:16638889. |
risperidone effectively increases rates of symptomatic remission of acute mania in people with bipolar disorder. |
2006-05-18 |
2023-08-12 |
Not clear |
| Martha Sajatovic, Subramoniam Madhusoodanan, Matthew A Fuller, Lakynetiew Aulakh, Daniel B Keato. Risperidone for bipolar disorders. Expert review of neurotherapeutics. vol 5. issue 2. 2006-04-14. PMID:15853488. |
risperidone for bipolar disorders. |
2006-04-14 |
2023-08-12 |
Not clear |
| Martha Sajatovic, Subramoniam Madhusoodanan, Matthew A Fuller, Lakynetiew Aulakh, Daniel B Keato. Risperidone for bipolar disorders. Expert review of neurotherapeutics. vol 5. issue 2. 2006-04-14. PMID:15853488. |
a number of controlled and open-label treatment trials have shown risperidone's efficacy and tolerability in the manic phase of bipolar disorder. |
2006-04-14 |
2023-08-12 |
Not clear |
| Martha Sajatovic, Subramoniam Madhusoodanan, Matthew A Fuller, Lakynetiew Aulakh, Daniel B Keato. Risperidone for bipolar disorders. Expert review of neurotherapeutics. vol 5. issue 2. 2006-04-14. PMID:15853488. |
risperidone has also been reported to be useful in the longer-term treatment of bipolar disorder. |
2006-04-14 |
2023-08-12 |
Not clear |